Comparison of ligase detection reaction and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis B

Wang, Xiaoling; Xie, Sheng‐Xue; Zhang, Ling; Yang, Weiyou; Wang, Xing; Jin, Hong-Zhi

doi:10.3748/wjg.14.120

Cited by 9 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 239 patients achieved the prevention of the progression of liver fibrosis with a tissue rate of 95%. Therefore, it has been pointed out that for HBeAg positive CHB patients, long-term use of ETV can prevent liver fibrosis and reverse liver cirrhosis [ 35 ]. Interferon (IFN) is a trace protein with high biological activity, which is generally divided into type I, type II, and type III [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Hui

Xian

Yang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To systematically evaluate the clinical value of tenofovir combined with recombinant human interferon α-2b in the treatment of chronic hepatitis B and to provide evidence-based medicine for its popularization and use. Methods. The randomized controlled trials (RCTs) of tenofovir combined with recombinant human interferon α-2b in the online database of PubMed, EMBASE, ScienceDirect, Cochrane Library, China knowledge Network (CNKI), China VIP database, Wanfang database, and China Biomedical Literature Database (CBM) were searched. The data included in this study were extracted by two independent researchers. After extracting the data of the study, the Cochrane manual 5.1.0 standard was used to evaluate the bias risk of all the literature included in this study. RevMan5.4 statistical software was used to analyze the collected data by meta. Results. Entecavir combined with recombinant human interferon α-2b can inhibit the activity of HBV polymerase and improve the inflammatory response of the liver. Recombinant human interferon α-2b can regulate immune function by inducing T cell differentiation and maturation and enhancing the production of cytokines. The systematic evaluation showed that entecavir combined with recombinant human interferon α-2b had higher serum HBeAg negative conversion rate, higher drug safety compared with entecavir alone, and improved liver function and immune status. Conclusion. Tenofovir combined with recombinant human interferon alpha-2b has a high serum HBeAg negative rate and safety profile for the treatment of chronic hepatitis B. The combination treatment can improve liver function and immune status in patients, but more studies with higher methodological quality and longer duration of intervention are needed for further validation.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Hui

Xian

Yang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Due to a fluorogenic reaction, the amount of reacted alkyne groups was calculated as previously described. 25 For the quantitative calculation of the alkyne groups using Anth-N 3 , four experiments were performed to measure the fluorescent enhancement: 39 (a) Anth-N 3 /DMSO (50 μL, 2.28 × 10 16 molecules, control experiment), (b) HES capsule dispersion/DMSO (control experiment), (c) Anth-N 3 / DMSO mixed with HES-NH 2 nanaocapsules (ratio 1:1, 2.28 × 10 16 molecules of each), and (d) Anth-N 3 /DMSO mixed with HES-D capsules (ratio 1:1, 2.28 × 10 16 molecules of each). For all experiments the samples (b−d) were stirred 24 h at 25 °C.…”

Section: Phosphate Buffered Saline (Dpbs-buffer -Mg 2 +mentioning

confidence: 99%

Interleukin-2 Functionalized Nanocapsules for T Cell-Based Immunotherapy

et al. 2016

View full text Add to dashboard Cite

A major demand on immunotherapy is the direct interference with specific immune cells in vivo. In contrast to antibody-engineered nanoparticles to control dendritic cells function, targeting of T cells for biomedical applications still remains an obstacle as they disclose reduced endocytic activities. Here, by coupling the cytokine interleukin-2 (IL-2) to the surface of hydroxyethyl starch nanocapsules we demonstrated a direct and specifc T cell targeting in vitro and in vivo by IL-2 receptor mediated internalization. For this purpose, defined amounts of azide-functionalized IL-2 were linked to alkyne-functionalized hydroxyethyl starch nanocapsules via copper free click reactions. In combination with validated quantification of the surface-linked IL-2 with anthracen azide this method allowed for engineering IL-2-functionalized nanocapsules for an efficient targeting of human and murine T cell populations with various IL-2 receptor affinities. This nanocapsule-mediated technique is a promising strategy for T cell-based immunotherapies and may be translated to other cytokine-related targeting systems.

show abstract

“…[20][21][22] The better detection of YI/VDD mixed type by pyrosequencing may be important for prediction of effects of entecavir against lamivudine-resistant variants, for YI/VDD mixed type was reported to be less sensitive to entecavir therapy than YIDD alone. 23 In conclusion, our experiments demonstrated that pyrosequencing had a detection limit of MUT/(MUT+WT) of 20%, and could finely quantify the ratios of MUT/(WT+MUT) to identify predominately WT, predominately MUT, and equal mixtures, thus revealing detailed heterogeneity information on YMDD mutations in the HBV-infected patients.…”

Section: Discussionmentioning

confidence: 99%

Clinical Application of Pyrosequencing in Detection of YMDD Mutations

Wen

2008

Laboratory Medicine

View full text Add to dashboard Cite

Background: It is well known that resistance to lamivudine commonly develops during the treatment of hepatitis B virus (HBV) infection; therefore, the detection of lamivudine-resistant mutants is of clinical importance.Methods: Serum samples from HBV-infected patients were analyzed for HBV mutations associated with lamivudine resistance (eg, YMDD) using PCR pyrosequencing assay. Results: We found that pyrosequencing had a detection limit of 20% mutant (MUT)/(MUT+ wildtype [WT]) in serum samples. Its sensitivity and specificity in the identification of YMDD mutations was 100% and 90%, respectively, and the accuracy rate in detection of artificially made predominately WT, predominately MUT, and equal mixtures of MUT and WT was 98.3%, 96.7%, and 95.0%, respectively. YMDD mutations were identified in 69.7% of 271 HBV patients treated with lamivudine for approximately 1 year.Conclusions: Pyrosequencing had a detection limit of MUT/(MUT+WT) of 20% and could finely identify predominately WT, predominately MUT, and equal mixtures, thus revealing detailed heterogeneity information on YMDD mutations in the HBV-infected patients.

show abstract

Comparison of ligase detection reaction and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis B

Cited by 9 publications

References 29 publications

Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Interleukin-2 Functionalized Nanocapsules for T Cell-Based Immunotherapy

Clinical Application of Pyrosequencing in Detection of YMDD Mutations

Contact Info

Product

Resources

About